Internal Medicine, Medical Oncology · Melbourne, FL
NPI
1861615130
Since 2007
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
8725 N Wickham Rd
Melbourne, FL, 32940
Phone (321) 253-4673
Groups this clinician bills Medicare through
Medicare paid, 2024
$6.3M
366,663 services
Medicare patients, 2024
1,794
Average age 76
Drug cost, 2024
$4.8M
1,953 prescriptions
Company payments, 2025
$461
From 4 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Amit C Barochia was code Q0138 (injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)), 41,310 times for 58 patients. In total Amit C Barochia billed 366,663 services in 156 codes, and Medicare paid $6.3M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-06-04.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 41,310 | 58 | $0.26 | $11K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 25,000 | 28 | $44.65 | $1.1M |
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 24,750 | 19 | $0.87 | $22K |
| J3262 Injection, tocilizumab, 1 mg | Office | 17,750 | 18 | $4.70 | $83K |
| J1453 Injection, fosaprepitant, 1 mg | Office | 16,500 | 30 | $0.11 | $1,881 |
| J9025 Injection, azacitidine, 1 mg | Office | 16,395 | 16 | $0.30 | $4,895 |
| J0897 Injection, denosumab, 1 mg | Office | 13,380 | 100 | $20.51 | $274K |
| Q5106 Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 11,210 | 64 | $5.80 | $65K |
| J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 10,818 | 18 | $35.21 | $381K |
| J1756 Injection, iron sucrose, 1 mg | Office | 9,400 | 30 | $0.17 | $1,639 |
| Q5123 Injection, rituximab-arrx, biosimilar, (riabni), 10 mg | Office | 3,250 | 14 | $31.78 | $103K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,902 | 64 | $0.09 | $262 |
| 99214 Office E&M - Established | Office | 2,548 | 941 | $90.44 | $230K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 1,901 | 43 | $0.71 | $1,355 |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 1,636 | 14 | $0.23 | $372 |
By year: 2022 $6.1M for 328,751 services; 2023 $5.7M for 344,933 services; 2024 $6.3M for 366,663 services.
Medicare prescription drug claims, 2024
In 2024, the drug Amit C Barochia prescribed most often to Medicare patients was Anastrozole, with 263 prescriptions and refills. In total Amit C Barochia wrote 1,953 Medicare prescriptions that cost $4.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 263 | 683 | 78 | $6,586 |
| Eliquis Apixaban | 104 | 166 | 31 | $92K |
| Tamoxifen Citrate Generic | 78 | 196 | 22 | $2,419 |
| Hydroxyurea Generic | 75 | 140 | 19 | $1,597 |
| Prednisone Generic | 72 | 85 | 23 | $267 |
| Oxycodone Hcl Generic | 66 | 66 | 17 | $1,449 |
| Letrozole Generic | 63 | 155 | 18 | $1,248 |
| Levothyroxine Sodium Generic | 62 | 98 | 13 | $522 |
| Abiraterone Acetate Generic | 43 | 43 | Under 11 | $260K |
| Alprazolam Generic | 43 | 43 | 16 | $244 |
| Tramadol Hcl Generic | 42 | 42 | 22 | $630 |
| Warfarin Sodium Generic | 39 | 85 | Under 11 | $467 |
| Xtandi Enzalutamide | 39 | 39 | Under 11 | $584K |
| Calquence Acalabrutinib Maleate | 37 | 37 | Under 11 | $372K |
| Dexamethasone Generic | 33 | 43 | 16 | $560 |
Brand drugs: 480 claims; generic drugs: 1,473 claims; opioid claims: 218.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Amit C Barochia $461 ($461 in general payments such as food, travel and fees) from 4 companies. The largest payer was Janssen Biotech, Inc. with $249.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.